Company Filing History:
Years Active: 2015-2017
Title: Vivek Khanna – A Pioneer in Chiral Inhibition Technologies
Introduction
Vivek Khanna, an accomplished inventor located in Lucknow, India, has made significant contributions to the field of medicinal chemistry. With two notable patents to his name, Khanna's innovations are focused on developing chiral compounds that serve as inhibitors of collagen-induced platelet activation. His work exemplifies the dedication to fostering advancements in pharmaceutical science.
Latest Patents
Vivek Khanna's latest patents include:
1. **Chiral 1-(4-methylphenylmethyl)-5-oxo-{N-[(3-t-butoxycarbonyl-aminomethyl)]-piperidin-1-yl}-pyrrolidine as inhibitors of collagen induced platelet activation and adhesion.**
2. **Chiral 1-(4-methylphenylmethyl)-5-oxo-{N-[(3-t-butoxycarbonyl-aminomethyl)]-piperidin-1-yl}-pyrrolidine-2-carboxamides as inhibitors of collagen induced platelet activation and adhesion.**
The present inventions provide chiral (2S)-1-(4-methylphenylmethyl)-5-oxo-(3S)-{N-[(3-t-butoxycarbonyl aminomethyl)]-piperidin-1-yl}-pyrrolidine-2-carboxamide, and (2S)-1-(4-methylphenylmethyl)-5-oxo-(3R)-{N-[(3-t-butoxycarbonyl amino methyl)]-piperidin-1-yl}-pyrrolidine-2-carboxamide. These chiral moieties are used as inhibitors of collagen-induced platelet adhesion and aggregation, mediating through collagen receptors. The inventions detail a novel process for preparing these chiral carboxamides while preventing racemization at the alpha-carboxylic center during N-alkylation.
Career Highlights
Khanna is affiliated with the Council of Scientific and Industrial Research, where he pursues innovative research and development. His dedication to the field and ability to create novel compounds have solidified his reputation as a skilled inventor. Khanna’s research activities predominantly focus on creating efficacious inhibitors to advance medical treatments and enhance patient care.
Collaborations
Throughout his career, Vivek Khanna has collaborated with notable colleagues, including Dinesh Kumar Dikshit and Madhu Dikshit. These collaborations have fostered a productive research environment that allows for the sharing of ideas and collective problem-solving in the pursuit of scientific innovation.
Conclusion
Vivek Khanna’s contributions to the field of medicinal chemistry and innovation in chiral inhibitors have the potential to make a substantial impact on the understanding and treatment of collagen-related conditions. His patents not only demonstrate his inventive capabilities but also emphasize the importance of collaboration within the scientific community. As he continues to advance research at the Council of Scientific and Industrial Research, Khanna’s work is poised to inspire future innovations in the field.